APOL1 INHIBITION BY VX-147 AS A TARGETED THERAPY FOR APOL1-MEDIATED KIDNEY DISEASE Pollak, M., Friedman, D., Barisoni, L., Falk, R., Gipson, D., Lipkowitz, M., Ojo, A., Chirieac, M., Xu, C., Fortier, A., Egbuna, O., Bunnage, M., Chertow, G., VX 147 Study Grp W B SAUNDERS CO-ELSEVIER INC. 2022: 769

View details for Web of Science ID 000797690900026